Dana-Farber Cancer Institute (Main)
Boston, MA
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
DREAMM5
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Learn more- Antibody Drug Conjugate (ADC)
- Gamma-Secretase Inhibitor
- BCMA
- Phase 2
- Has results
Accepting patients
NK Cell Therapy With BHV-1100
Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients
Learn more- Natural Killer Cells
- CD38
- Phase 1
Accepting patients
CFT7455
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Learn more- Phase 1/2
Accepting patients
CAMMA-2
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)
Learn more- Bispecific Antibody
- FCRH5
- Phase 1/2
Accepting patients
CA057-003
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Learn more- CELMoD
- Phase 1/2
Accepting patients
OPN-662
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma
Learn more- BET Inhibitor
- Phase 1
Not yet accepting
EXCALIBER RRMM
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Learn more- CELMoD
- Randomization
- Phase 3
Not yet accepting
SUCCESSOR-1
Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Learn more- CELMoD
- Randomization
- Phase 3
Not yet accepting
SUCCESSOR-2
Phase 3 Study Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Learn more- CELMoD
- Randomization
- Phase 3
Not yet accepting
QUINTESSENTIAL
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more- CAR T Cell
- GPRC5D
- Phase 2
11 hidden based on your filters. Show All